Fate Therapeutics recently announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for the lupus treatment candidate FT819.

Current treatment options for systemic lupus erythematosus (SLE) consists of glucocorticoids, antimalarials, immunosuppressives, and a few biologics, approved or of 'off-label'. Through judicious ...

talk with your doctor about the best treatment options for your condition. Saphnelo is a prescription medication used to treat a certain kind of lupus called systemic lupus erythematosus (SLE).

May 23, 2024 — Treatment ... fix a defect that causes lupus, and hope their discovery will offer effective long-term ... Incurable Autoimmune Disease Systemic Lupus Erythematosus (SLE): New ...

In a new letter, published in the Journal of the European Academy of Dermatology and Venereology, members of the lupus ...

Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has described immunoproteasome inhibitors reported to be useful for the treatment of systemic lupus erythematosus and arthritis.

Fate Therapeutics (NASDAQ:FATE) announced that the U.S. FDA granted Regenerative Medicine Advanced Therapy designation to FT819 for the treatment of lupus. FT819 is an experimental treatment currently ...

Kangpu Biopharmaceuticals, Ltd. announced today that the Center for Drug Evaluation (CDE) of China's National Medical ...

The following is a summary of “Factors associated with worsening interstitial fibrosis/tubular atrophy in lupus nephritis ...

Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity and remission, and more time spent in those states, vs. standard therapy ...